Interestingly, while germline TC-NER pathway mutations are not associated with cancer, somatic TC-NER pathway mutations have been identified in a subset of epithelial ovarian cancers with increased sensitivity to platinum-based chemotherapy and PARP inhibitors [73,74]. The gene discussed is PARP1; the disease is cancer.